Table 2.

Correlation between increasing EFS and use of health care

Use of health care per mo of OSCoefficient of correlationP
r95% CI
All patients    
 Overall use of health care −0.45 −0.53 to −0.37 <.001 
 Clinic visits −0.38 −0.46 to −0.29 <.001 
 ER visits −0.15 −0.24 to −0.05 .004 
 Hospital admissions −0.34 −0.43 to −0.25 <.001 
 Consultations from other services −0.39 −0.47 to −0.30 <.001 
 Blood product transfusions −0.18 −0.28 to −0.09 <.001 
 Laboratory studies −0.51 −0.58 to −0.44 <.001 
 Imaging studies −0.38 −0.46 to −0.29 <.001 
 Invasive procedures −0.49 −0.56 to −0.41 <.001 
Patients with CR (n = 286)    
 Overall use of health care −0.52 −0.60 to −0.43 <.001 
 Combined clinic visits, ER visits, hospitalizations, and consultations −0.51 −0.59 to −0.42 <.001 
 Combined invasive procedures, imaging studies, and laboratory studies −0.60 −0.67 to −0.52 <.001 
 Blood product transfusions −0.20 −0.31 to −0.09 <.001 
 Hospitalizations −0.36 −0.46 to −0.25 <.001 
 ER visits −0.17 −0.28 to −0.06 .003 
Overall use of health care in ELN risk groups    
 Favorable (n = 29) −0.36 −0.64 to 0.01 .06 
 Intermediate (n = 230) −0.40 −0.50 to −0.29 <.001 
 Adverse (n = 141) −0.55 −0.66 to −0.42 <.001 
Overall use health care according to age, y    
 <65 (n = 193) −0.43 −0.54 to −0.31 <.001 
 ≥65 (n = 207) −0.41 −0.52 to −0.29 <.001 
Overall use of health care according to therapy    
 Intensive chemotherapy with or without other agents (n = 188)* −0.47 −0.57 to −0.34 <.001 
 HMA with or without other agents or chemotherapy (n = 109)† −0.47 −0.61 to −0.20 <.001 
 NIC with or without other agents (n = 93)* −0.43 −0.58 to −0.24 <.001 
Use of health care per mo of OSCoefficient of correlationP
r95% CI
All patients    
 Overall use of health care −0.45 −0.53 to −0.37 <.001 
 Clinic visits −0.38 −0.46 to −0.29 <.001 
 ER visits −0.15 −0.24 to −0.05 .004 
 Hospital admissions −0.34 −0.43 to −0.25 <.001 
 Consultations from other services −0.39 −0.47 to −0.30 <.001 
 Blood product transfusions −0.18 −0.28 to −0.09 <.001 
 Laboratory studies −0.51 −0.58 to −0.44 <.001 
 Imaging studies −0.38 −0.46 to −0.29 <.001 
 Invasive procedures −0.49 −0.56 to −0.41 <.001 
Patients with CR (n = 286)    
 Overall use of health care −0.52 −0.60 to −0.43 <.001 
 Combined clinic visits, ER visits, hospitalizations, and consultations −0.51 −0.59 to −0.42 <.001 
 Combined invasive procedures, imaging studies, and laboratory studies −0.60 −0.67 to −0.52 <.001 
 Blood product transfusions −0.20 −0.31 to −0.09 <.001 
 Hospitalizations −0.36 −0.46 to −0.25 <.001 
 ER visits −0.17 −0.28 to −0.06 .003 
Overall use of health care in ELN risk groups    
 Favorable (n = 29) −0.36 −0.64 to 0.01 .06 
 Intermediate (n = 230) −0.40 −0.50 to −0.29 <.001 
 Adverse (n = 141) −0.55 −0.66 to −0.42 <.001 
Overall use health care according to age, y    
 <65 (n = 193) −0.43 −0.54 to −0.31 <.001 
 ≥65 (n = 207) −0.41 −0.52 to −0.29 <.001 
Overall use of health care according to therapy    
 Intensive chemotherapy with or without other agents (n = 188)* −0.47 −0.57 to −0.34 <.001 
 HMA with or without other agents or chemotherapy (n = 109)† −0.47 −0.61 to −0.20 <.001 
 NIC with or without other agents (n = 93)* −0.43 −0.58 to −0.24 <.001 

ELN, European LeukemiaNet 2017; HMA, hypomethylating agent; NIC, nonintensive chemotherapy.

*

Other agents included non-chemotherapy, targeted therapy, and immunotherapy.

†

Other agents included non-chemotherapy, targeted therapy, immunotherapy, and low-dose chemotherapy.

View Large
This Feature Is Available To Subscribers Only

or Create an Account

Close Modal
Close Modal